Riverine Ventures Research
Investment Thesis
Riverine Ventures is a life science and healthcare venture capital firm based in Sausalito, California, founded in 2021. Its homepage says it invests in and nurtures the growth of next generation life science and healthcare companies. Its flagship venture strategy, called P9, partners with entrepreneurs working on breakthrough biomedical technologies at early stage private companies. The firm says it is driven by advances in precision medicine and focuses on therapeutics, devices, diagnostics and data-driven insights that improve outcomes for patients with unmet medical needs. It states high conviction on both the scientific and clinical value propositions of its companies, and it works closely with management teams to execute with capital efficiency. Search snippets from its About page describe the firm as a next-generation VC providing capital, networks and guidance to entrepreneurs building at the intersection of medicine and AI.
Stage Focus
Third-party profiles describe the firm as early stage, with a Series A emphasis. The one sourced round found is CellFE's $22M Series A in September 2023, led by M Ventures, in which Riverine participated alongside GreatPoint Ventures and existing investors. The firm does not publish a stage or check size, so both are treated as low confidence and left unset.
Check Size
Not disclosed on the site. No check size range is submitted.
Lead Tendency
The only sourced round (CellFE Series A) shows Riverine participating behind another lead. Lead tendency is recorded as unknown.
Recent Activity
The site does not list recent deals or news. The sourced activity is the September 2023 CellFE Series A participation. The firm's portfolio page was refreshed in May 2026 (logo uploads dated 2026-05), which suggests the firm is active, but fund size and fund status are not published.
Portfolio Highlights
The homepage lists fifteen representative equity holdings:
- Genomenon (genomic intelligence)
- iantrek
- Intelliscopes
- Inflammatix (host response diagnostics)
- Magnolia Medical Technologies
- KeifeRx
- Vynca
- SONALASENSE (sonodynamic cancer therapy)
- Adventris Pharmaceuticals
- AEYE Health (AI eye screening)
- Artisight (smart hospital platform)
- Clarapath (pathology automation)
- Circularis (acquired by Ginkgo Bioworks)
- Corsair Pharma
- Gauss Surgical (acquired by Stryker)
The founder's biography also lists earlier investments and exits made before and alongside the firm, including Rayze Bio (acquired by Bristol Myers Squibb), Paradigm Cancer Diagnostics (acquired by Exact Sciences), SilverCloud (acquired by Amwell), Level Ex (acquired by Brainlab), Doctor on Demand and Aptinyx.
Team
- Garrett Vygantas, MD, MBA, Founder & Managing Partner: physician and Kauffman Fellow with over 20 years across biopharma, life sciences, medtech and digital health. Previously invested for The 4100 Group, OSF Healthcare, Jump Capital and Burrill & Co. Founding CEO of TherOptix, NewBridge Pharmaceuticals and Mitre Medical, and Chief Business Officer of Corsair Pharma. Helped launch Lucentis at Genentech and worked in healthcare investment banking at Cowen. Sits on boards or advises Adventris, AEYE Health, Artisight, CellFE, Ceria Therapeutics, Corsair, Eliksa, HealthBridge, Inflammatix, KeifeRx, Mediphage and Pieces Technologies.
- Scott Robert Lancaster, MD, MBA, Partner: board certified diagnostic radiologist and venture investor. Former Managing Director and Chief Investment Officer of The 4100 Group, and co-lead and clinical director of Spectrum Health Ventures, where he led investments in Arivale, Gauss Surgical, Ciitizen and Vynca.
The site states the partners have a combined 30 years across healthcare and life sciences.
Decision Process
Not published. A small partnership with physician-investors who also take board and advisor seats is the most consistent reading, so the decision process is left unset.
Founder Preferences
High calibre entrepreneurs with breakthrough biomedical technology, a strong scientific and clinical case for unmet patient need, and a capital efficient plan. The partners' clinical backgrounds suggest they favor founders who can use the physician network the firm offers.
Geographic Focus
The firm is based in Sausalito, California. The portfolio spans US companies in several regions (for example Inflammatix in California, Clarapath in New York, Vynca in Michigan and Washington), and the firm states no geographic limit. No geography preference is submitted.
Gaps
No disclosed fund size, check size, stage range, or contact email. The site has only Home, About Us and Contact pages, with the About and Contact pages repeating the partner biographies. Captions on the portfolio logo wall were used for company names; domains are only set where the About page links matched a company name.